However, AbbVie also paid dividends during these 10 years. Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — you can become an ...

An AbbVie research and development lab in San Francisco. (Brian L. Frank for The Wall Street Journal) Drugmaker AbbVie plans to invest more than $10 billion in domestic manufacturing and other ...

AbbVie Inc. took a little shot at the Trump administration’s trade policy, as the drugmaker said Friday that rather than tariffs, tax reform is the key to boosting U.S. manufacturing. The ...

AbbVie stock jumped Friday after the pharma titan hiked its full-year outlook on the back of strength from its immunology powerhouses Skyrizi and Rinvoq. The duo now completely outearn AbbVie's ...

AbbVie Inc. ABBV, a biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company's stock traded at ...

AbbVie stock outperformed S&P 500 with a +16% to 9.41% return since November 2023, despite Humira revenue declining 38% to $8.99 billion. Immunology drugs Skyrizi and Rinvoq grew over 50% year ...

AbbVie is poised to grow this year for the first time since Humira's U.S. patent expired. The dividend yields a generous 3.7% and features decades of consistent growth. While tariffs, politics ...

Pharmaceutical company AbbVie (NYSE:ABBV) in Q1 CY2025, with sales up 8.4% year on year to $13.34 billion. Its non-GAAP profit of $2.46 per share was 2.6% above analysts’ consensus estimates.

Investors in AbbVie Inc (Symbol: ABBV) saw new options become available today, for the June 27th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV ...

AbbVie Inc.’s (NYSE:ABBV) year is off to a very strong start. The company beat Q1 2025 revenue and EPS estimates and raised the full-year EPS guidance range by $0.10 and the full-year revenue ...

AbbVie Inc. raised its profit outlook for the year on better-than-expected sales from newer autoimmune treatments, but warned its forecast doesn’t take into account any potential changes in ...